company background image
GLTO

Galecto NasdaqGS:GLTO Stock Report

Last Price

US$1.94

Market Cap

US$49.3m

7D

-6.3%

1Y

-48.7%

Updated

26 Sep, 2022

Data

Company Financials +
GLTO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GLTO Stock Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.

Galecto, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Galecto
Historical stock prices
Current Share PriceUS$1.94
52 Week HighUS$3.92
52 Week LowUS$1.17
Beta0
1 Month Change-22.71%
3 Month Change7.78%
1 Year Change-48.68%
3 Year Changen/a
5 Year Changen/a
Change since IPO-87.07%

Recent News & Updates

Jul 29

Galecto GAAP EPS of -$0.67 beats by $0.02

Galecto press release (NASDAQ:GLTO): Q2 GAAP EPS of -$0.67 beats by $0.02. Cash, cash equivalents, and investments as of June 30, 2022 were approximately $85.9 million.

Jun 30
We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

GLTOUS BiotechsUS Market
7D-6.3%-5.3%-6.9%
1Y-48.7%-30.6%-23.7%

Return vs Industry: GLTO underperformed the US Biotechs industry which returned -30% over the past year.

Return vs Market: GLTO underperformed the US Market which returned -23% over the past year.

Price Volatility

Is GLTO's price volatile compared to industry and market?
GLTO volatility
GLTO Average Weekly Movement11.2%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: GLTO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: GLTO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201140Hans Schambyehttps://galecto.com

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Galecto, Inc. Fundamentals Summary

How do Galecto's earnings and revenue compare to its market cap?
GLTO fundamental statistics
Market CapUS$49.27m
Earnings (TTM)-US$59.93m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GLTO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$59.93m
Earnings-US$59.93m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.36
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GLTO perform over the long term?

See historical performance and comparison